

**Supplemental Information**


**Targeting Root Cause by Systemic scAAV9-h $\beta$ DS**

**Gene Delivery: Functional Correction**

**and Reversal of Severe MPS II in Mice**


Haiyan Fu, Kim Zaraspe, Naoko Murakami, Aaron S. Meadows, Ricardo J. Pineda, Douglas M. McCarty, and Joseph Muenzer

**Figure S1**



**Figure S1. scAAV9-mCMV-hIDS vector genome.** ITR: wt AAV2 terminal repeat; dITR: AAV2 terminal repeat with deletion of terminal resolution site to force generation of self-complementary dimeric genomes; mCMV: a truncated 173bp mini CMV promoter; hIDS: human iduronate sulfatase coding region cDNA; Poly A: SV40 polyadenylation signal.

## Supplementary Figure S2



**Supplementary Figure S2 Differential biodistribution of systemically delivered scAAV9-mCMV-hIDS vector in MPS II and WT mice.** MPS II and WT mice were treated at age 1-2m with an IV injection of  $5 \times 10^{13} \text{ vg/kg}$  scAAV9-mCMV-hIDS. Tissues were assayed by qPCR for scAAV9-hIDS vector genome at 5 days or 1m pi (n=4/group).

**Table S1. Tumor incidence in AAV9-treated MPS II and non-treated WT mice at endpoints**

Mouse ID #	GT	Vector dose (vg/kg)	Injection age (m)	Test age (m)	Tumors		$10^5$ vg/ $\mu$ g gDNA
					Gross	Microscopic <sup>#</sup>	
<b>855</b>	MPS II	$2.5 \times 10^{12}$	1	20	Liver	ND*	0.405 (T1)
							6.850 (T2)
<b>858</b>	MPS II	$2.5 \times 10^{12}$	1	21	Liver	ND*	0.366 (T1)
							9.550 (T2)
							0.021 (T3)
<b>870</b>	MPS II	$2.5 \times 10^{12}$	1	26	Liver	NE**	15.2 (T1)
							0.396 (T2)
<b>882</b>	MPS II	$2.5 \times 10^{12}$	1	21	No	Histiocytic sarcoma (liver, spleen)	N/A
<b>151</b>	MPS II	$5 \times 10^{12}$	1	25	Liver	NE**	2.92
<b>173</b>	MPS II	$5 \times 10^{12}$	1	16	No	Histiocytic sarcoma (liver, Kidney, spleen)	N/A
<b>206</b>	MPS II	$5 \times 10^{12}$	1	16	Liver	ND*	1.47
<b>235</b>	MPS II	$5 \times 10^{12}$	1	25	Liver	ND*	1.42 (T1)
							0.785 (T2)
<b>429</b>	MPS II	$5 \times 10^{12}$	3	17	Liver	ND*	8.220 (T1)
							5.07 (T2)
<b>691</b>	MPS II	$5 \times 10^{12}$	6	22	Liver	ND*	8.60 (T1)
							1.00 (T2)
							1.23 (T3)
<b>1027</b>	MPS II	$1 \times 10^{13}$	6	23	Liver	NE**	0.712 (T1)
							0.943 (T2)
<b>1035</b>	MPS II	$1 \times 10^{13}$	6	25	Liver	NE**	1.592
<b>1036</b>	MPS II	$1 \times 10^{13}$	6	21	Liver	ND*	1.611
<b>1132</b>	MPS II	$2 \times 10^{13}$	6	21	Liver	ND*	21.9 (T1)
							20.7 (T2)
<b>1062</b>	MPS II	$2 \times 10^{13}$	9	21	Liver	ND*	1.20 (T1)
							38.5 (T2)
<b>148</b>	WT	NT	N/A	29	Liver	Histiocytic sarcoma (liver, Kidney, lung)	9 tumors, NE**
<b>294</b>	WT	NT	N/A	28	Liver	ND*	<0.001
<b>677</b>	WT	NT	N/A	24	Liver	ND*	ND*
<b>53</b>	WT	NT	N/A	26	Liver	NE**	<0.001(T1)
							<0.001(T2)
<b>862</b>	WT	NT	N/A	26	Liver	NE**	<0.001
<b>316</b>	WT	NT	N/A	30	Liver	NE**	<0.001(T1)
							<0.001(T2)
							<0.001(T3)
<b>332</b>	WT	NT	N/A	23	Liver	NE**	<0.001
<b>294</b>	WT	NT	N/A	28	Liver	NE**	<0.001
<b>402</b>	WT	NT	N/A	28	Liver	NE**	ND*

<sup>#</sup>: Histopathology examination on H&E-stained non-tumor tissues; \*ND: not detected; \*\*NE: not examined.